CD19 and systemic lupus erythematosus: A research team in Germany documented a case where a CD19 CAR T-cell product was administered to eliminate B cells in a patient with SLE.49 Following this, the researchers extended their investigation to 5 patients, noting a remission of SLE clinical symptoms in all patients within 3 months.